The Biostatistics component of the Administrative-Biostatistics Core will reside within the University of Pittsburgh Cancer Institute's (UPCI) Biostatistics Facility, which provides clinical and basic-science investigators in UPCI with statistical expertise in design, analysis, and reporting of cancer-related research studies. These cover basic-science studies;phase I and phase II oncology clinical trials;epidemiologic studies, including those related to cancer prevention and awareness;and investigations of behavioral and health sequelae of cancer treatment. Biostatistics will support all three research projects. We will collaborate with investigators on statistical aspects of the design of in vitro and in vivo laboratory-based studies as new data come to light, and perform both exploratory and confirmatory statistical analyses of the resulting data from key experiments. For the clinical trials that are planned in Project 1 and Project 3, we will collaborate with basic scientists and clinicians on finalizing the development of protocols that are methodologically sound, and that will pass scientific, ethical, and regulatory review. We will perform interim analyses of safety for the clinical trials, and final analyses of their data on safety, immune response, and treatment efficacy. We will work with the project investigators, UPCI Informatics, and with UPCI Clinical Research Services to ensure that the requisite laboratory and clinical-trial data are available for statistical analyses. We will collaborate with the project investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA132714-05
Application #
8469294
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$173,423
Indirect Cost
$58,685
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Downs-Canner, Stephanie; Guo, Zong Sheng; Ravindranathan, Roshni et al. (2016) Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther 24:1492-501
Radomski, Michal; Zeh, Herbert J; Edington, Howard D et al. (2016) Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. J Immunother Cancer 4:24
Wong, Jeffrey L; Obermajer, Nataša; Odunsi, Kunle et al. (2016) Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res 4:303-11
Francis, Lily; Guo, Zong Sheng; Liu, Zuqiang et al. (2016) Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget 7:22174-85
Kalinski, Pawel; Gingrich, Jeffrey R (2015) Toward improved effectiveness of bladder cancer immunotherapy. Immunotherapy 7:1039-42
Zeh, Herbert J; Downs-Canner, Stephanie; McCart, J Andrea et al. (2015) First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther 23:202-14
Liu, J Y; Li, F; Wang, L P et al. (2015) CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer 113:747-55
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847-57

Showing the most recent 10 out of 56 publications